12:00 AM
 | 
Apr 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ampyra dalfampridine: Phase II data

Acorda said data from a double-blind, placebo-controlled, crossover, U.S. Phase II trial in 24 patients with cerebral palsy suggest that twice-daily 10 mg oral dalfampridine extended release (ER) tablets have "potential treatment activity" on measures of walking and hand strength. The company said the data are still being analyzed to...

Read the full 229 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >